aTyr Pharma, Inc. (LIFE)

1.5950 -0.0250 (-1.54%) As of 03:37PM EDT. Market open.

aTyr Pharma, Inc.

10240 Sorrento Valley Road
Suite 300
San Diego, CA 92121
United States
858 731 8389
https://www.atyrpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 56

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sanjay S. Shukla M.D., M.S.	President, CEO & Director	768.18k	N/A	1972
Ms. Jill M. Broadfoot	Chief Financial Officer	544.75k	N/A	1962
Ms. Nancy E. Denyes Krueger	General Counsel & Corporate Secretary	518.2k	N/A	1968
Xiang-Lei Yang Ph.D.	Founder	N/A	N/A	N/A
Ms. Ashlee Dunston	Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. Peter Villiger	Vice President of Corporate Development	N/A	N/A	N/A
Ms. Danielle Campbell	VP of Human Resource	N/A	N/A	N/A
Dr. Leslie Nangle Ph.D.	Vice President of Research	N/A	N/A	N/A
Dr. Ying J. Buechler Ph.D.	Executive Director of Biologics Development & Manufacturing	N/A	N/A	N/A
Dr. David J. King Ph.D.	Scientific Consultant	327.31k	N/A	1959

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Corporate governance

aTyr Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.